Aliases & Classifications for Gout

Summaries for Gout

MedlinePlus : 40 Gout is a common, painful form of arthritis. It causes swollen, red, hot and stiff joints. Gout happens when uric acid builds up in your body. Uric acid comes from the breakdown of substances called purines. Purines are in your body's tissues and in foods, such as liver, dried beans and peas, and anchovies. Normally, uric acid dissolves in the blood. It passes through the kidneys and out of the body in urine. But sometimes uric acid can build up and form needle-like crystals. When they form in your joints, it is very painful. The crystals can also cause kidney stones. Often, gout first attacks your big toe. It can also attack ankles, heels, knees, wrists, fingers, and elbows. At first, gout attacks usually get better in days. Eventually, attacks last longer and happen more often. You are more likely to get gout if you Are a man Have family member with gout Are overweight Drink alcohol Eat too many foods rich in purines Gout can be hard to diagnose. Your doctor may take a sample of fluid from an inflamed joint to look for crystals. You can treat gout with medicines. Pseudogout has similar symptoms and is sometimes confused with gout. However, it is caused by calcium phosphate, not uric acid. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Gout, also known as arthritis, gouty, is related to hyperuricemic nephropathy, familial juvenile, 1 and phosphoribosylpyrophosphate synthetase superactivity, and has symptoms including sciatica, muscle cramp and back pain. An important gene associated with Gout is HPRT1 (Hypoxanthine Phosphoribosyltransferase 1), and among its related pathways/superpathways are Purine metabolism and Pyrimidine metabolism (KEGG). The drugs Colchicine and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include joint, kidney and heart, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology : 12 An arthritis that has material basis in uric acid crystal deposits located in joint.

PubMed Health : 59
About gout: Gout is a metabolic disorder which causes inflammation of the joints. In acute cases, some joints swell up within just a few hours and become very sensitive to pain. The inflammation is triggered by tiny needle-shaped crystals of uric acid that build up mostly in the joints. These crystals may form if there is too much uric acid in the body. The inflammation normally goes away on its own within one to two weeks. The pain can be relieved by taking anti-inflammatory or pain-relieving medication.Most people with gout experience acute attacks every now and then. Months or even years can pass between attacks. There are a number of options to prevent them. Some people already notice an improvement if they avoid certain foods and other possible triggers. Others need to take medication to reduce their uric acid levels over the long-term. Medication is a good option if the attacks become more frequent or there is a risk of complications. It is important to make sure that the inflammation does not become chronic and damage the joints.

Wikipedia : 72 Gout is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and... more...

Related Diseases for Gout

Diseases related to Gout via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 hyperuricemic nephropathy, familial juvenile, 1 33.3 HPRT1 SLC22A12 UMOD
2 phosphoribosylpyrophosphate synthetase superactivity 33.2 HPRT1 PRPS1
3 kelley-seegmiller syndrome 32.6 APRT HPRT1
4 lesch-nyhan syndrome 31.9 ADSL APRT HPRT1 XDH
5 hyperuricemia 30.1 ABCG2 HPRT1 SLC17A1 SLC17A3 SLC22A12 SLC2A9
6 nephrolithiasis 29.5 APRT SLC22A12 SLC2A9 UMOD
7 adenine phosphoribosyltransferase deficiency 29.5 APRT HPRT1 XDH
8 uric acid concentration, serum, quantitative trait locus 1 11.6
9 familial juvenile hyperuricaemic nephropathy 11.6
10 chondrocalcinosis 2 11.5
11 arthritis 11.3
12 crystal arthropathies 11.2
13 medullary cystic kidney disease 2 11.0
14 uric acid concentration, serum, quantitative trait locus 4 11.0
15 autosomal dominant tubulointerstitial kidney disease, umod-related 10.8
16 nephronophthisis-like nephropathy 1 10.8
17 autosomal dominant tubulointerstitial kidney disease 10.8
18 occipital neuralgia 10.8
19 nephrolithiasis, uric acid 10.5 HPRT1 XDH
20 hypouricemia, renal, 1 10.4 HPRT1 SLC22A12 SLC2A9
21 acute urate nephropathy 10.2 CARMIL1 SLC22A12
22 tinea favosa 10.2 IL1B NLRP3
23 vulvar vestibulitis syndrome 10.1 IL1B NLRP3
24 kidney disease 10.1
25 cervical adenitis 10.1 IL1B NLRP3
26 arthropathy 10.1
27 familial cold autoinflammatory syndrome 1 10.1 IL1B NLRP3
28 chronic kidney failure 10.1
29 schnitzler syndrome 10.0 IL1B NLRP3
30 episodic pain syndrome, familial, 1 10.0
31 rheumatoid arthritis 10.0
32 hereditary xanthinuria 10.0 APRT XDH
33 chronic recurrent multifocal osteomyelitis 10.0 IL1B NLRP3
34 urate oxidase, pseudogene 10.0
35 body mass index quantitative trait locus 11 9.9
36 body mass index quantitative trait locus 9 9.9
37 body mass index quantitative trait locus 8 9.9
38 body mass index quantitative trait locus 4 9.9
39 body mass index quantitative trait locus 10 9.9
40 body mass index quantitative trait locus 7 9.9
41 body mass index quantitative trait locus 12 9.9
42 body mass index quantitative trait locus 14 9.9
43 body mass index quantitative trait locus 18 9.9
44 osteoarthritis 9.9
45 aging 9.9
46 osteoarthritis with mild chondrodysplasia 9.9
47 chondrocalcinosis 9.9
48 bursitis 9.9
49 septic arthritis 9.9
50 myocardial infarction 9.8

Comorbidity relations with Gout via Phenotypic Disease Network (PDN): (show all 27)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Benign Essential Hypertension Bladder Neck Obstruction
Bronchitis Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Ischemic Heart Disease Kidney Disease
Mitral Valve Disease Osteoarthritis
Peripheral Vascular Disease Prostate Cancer
Prostatic Hypertrophy Sinoatrial Node Disease
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Gout:



Diseases related to Gout

Symptoms & Phenotypes for Gout

UMLS symptoms related to Gout:


sciatica, muscle cramp, back pain

MGI Mouse Phenotypes related to Gout:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 UMOD XDH ABCG2 ALDH2 APRT HPRT1
2 immune system MP:0005387 9.65 XDH ABCG2 ALDH2 APRT HPRT1 IL1B
3 renal/urinary system MP:0005367 9.28 XDH ABCG2 ALDH2 APRT HPRT1 NLRP3

Drugs & Therapeutics for Gout

PubMedHealth treatment related to Gout: 59

There are two main approaches to treating gout:Acute: Treatment of pain caused by a gout attackLong-term: Prevention of further gout attacks, chronic inflammation and joint damageAcute gout attacks are usually treated with anti-inflammatory painkillers like ibuprofen, indometacine or naproxene. If these medications are not an option or do not provide enough relief, the special gout medication colchicine is an alternative. Colchicine must be taken within the first 36 hours of a gout attack. Cortisone products, usually in tablet form, are another treatment option. If a single drug cannot offer enough pain relief, treatments can be combined. Cooling the affected joint can also help and most people find it very soothing.The aim of long-term gout treatment is to permanently lower uric acid levels, with a view to preventing further gout attacks and keeping it from becoming chronic. Uric acid levels can be lowered by doing general things like avoiding certain foods, but regular medication may also be necessary.  Medicine can be prescribed if gout attacks become more frequent or tophi have already formed. Medications are also recommended if complications have already occurred or are expected, and for people with reduced kidney function.If you start long-term treatment with medication, your uric acid levels will be tested every two to three months. This is done to ensure that levels are too low for crystals to form. Less frequent check-ups, for example once a year, are enough at a later stage.Many people with gout are also affected by high blood pressure or diabetes. Getting treatment for those conditions can also help to lower the risk of some cardiovascular diseases.

Drugs for Gout (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 644)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-86-8 2833 6167
2
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
3
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 9579578 4594
4
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22204-53-1 156391 1302
5
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
6
Codeine Approved, Illicit Phase 4,Phase 2,Phase 3 76-57-3 5284371
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 93-14-1 3516
8
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 1 27203-92-5 33741
9
Amitriptyline Approved Phase 4 50-48-6 2160
10
Cyclobenzaprine Approved Phase 4 303-53-7 2895
11
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
12
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 76-42-6 5284603
13
Allopurinol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 315-30-0 2094
14
Indomethacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53-86-1 3715
15
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2 15307-86-5 3033
16
Probenecid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-66-9 4911
17
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134774-45-1
18
Nitric Oxide Approved Phase 4,Phase 3,Phase 1,Phase 2 10102-43-9 145068
19
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
20
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1 15687-27-1 3672
21
Sumatriptan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 103628-46-2 5358
22
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
23
Ketorolac Approved Phase 4,Phase 3 74103-06-3, 66635-83-4 3826
24
Nifedipine Approved Phase 4,Phase 3,Phase 2 21829-25-4 4485
25
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
26
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1 144060-53-7 134018
27
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 73590-58-6 4594
28
Etoricoxib Approved, Investigational Phase 4,Phase 3 202409-33-4 123619
29
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
30
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
32
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
33
Theophylline Approved Phase 4,Phase 1 58-55-9 2153
34
Coal tar Approved Phase 4,Phase 3 8007-45-2
35
Ephedrine Approved Phase 4,Phase 3,Phase 1 299-42-3 9294
36
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1 90-82-4 7028
37
Ranibizumab Approved Phase 4 347396-82-1 459903
38
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
39
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
40
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
41
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
42
Morphine Approved, Investigational Phase 4 57-27-2 5288826
43
Meloxicam Approved, Vet_approved Phase 4,Phase 3,Phase 2 71125-38-7 54677470 5281106
44
Carbidopa Approved Phase 4,Phase 2,Phase 1 28860-95-9 38101 34359
45
Levodopa Approved Phase 4,Phase 2,Phase 1 59-92-7 6047
46
Dipyridamole Approved Phase 4 58-32-2 3108
47
Dinoprostone Approved Phase 4,Phase 3 363-24-6 5280360
48
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 657311 5754
49
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
50
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109

Interventional clinical trials:

(show top 50) (show all 830)

# Name Status NCT ID Phase Drugs
1 Post-MI PET Scan Imaging of Inflammation Unknown status NCT02281305 Phase 4 Colchicine
2 Colchicine in ST-elevation Myocardial Infarction Unknown status NCT01936285 Phase 4 Colchicine 2 mg loading dose; 0.5 mg bid for 5 days;Placebo
3 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4 Colchicine;Placebo
4 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
5 Postoperative Analgesia in Laminectomy Unknown status NCT02255955 Phase 4 550 mg naproxen sodium and 30mg codeine;300 mg paracetamol and 30 mg codeine;placebo tablet
6 Efficacy of Intravenous Naproksen Sodium+Codein and Paracetamol+Codein on Postoperative Pain on Postoperative Pain Unknown status NCT02252614 Phase 4 naproxen sodium codein;paracetamol codein;Placebo
7 A Randomized Study of Three Medication Regimens for Acute Low Back Pain Unknown status NCT01587274 Phase 4 Naproxen;Cyclobenzaprine;Oxycodone/ acetaminophen
8 Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial Unknown status NCT00615875 Phase 4 naproxen;placebo
9 Does Allopurinol Prolong a Treated, Acute Gout Flare? Completed NCT01988402 Phase 4 allopurinol;Placebo (sugar pill)
10 Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol Completed NCT01451645 Phase 4 Colchicine (Colcrys®);placebo;allopurinol
11 Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout Completed NCT01310673 Phase 4 Allopurinol;Placebo
12 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
13 Colchicine Or Naproxen Treatment for ACute gouT Completed NCT01994226 Phase 4 Low-dose colchicine;Naproxen 750 mg/250 mg
14 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
15 A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED) Completed NCT00142558 Phase 4 MK0663; etoricoxib / Duration of Treatment: 5 Days;Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days
16 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed NCT01112982 Phase 4 Febuxostat;Colchicine
17 Allopurinol Outcome Study Completed NCT01391325 Phase 4 Allopurinol
18 Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout Completed NCT00170781 Phase 4 Lumiracoxib
19 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
20 Optimal Administration of Allopurinol in Dialysis Patients Completed NCT02477488 Phase 4 Allopurinol
21 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
22 Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Completed NCT01472692 Phase 4 Febuxostat
23 Postmarketing Study to Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM Completed NCT01529099 Phase 4
24 Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Completed NCT00688480 Phase 4 Placebo;Allopurinol
25 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4 olmesartan medoxomil;olmesartan medoxomil+probenecid
26 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4 Allopurinol;Placebo (for allopurinol)
27 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed NCT01763996 Phase 4 Febuxostat;Febuxostat placebo
28 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4 Febuxostat;Placebo
29 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
30 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
31 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
32 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
33 The Effect of Uric Acid Lowering in Type 1 Diabetes Completed NCT02344602 Phase 4 Febuxostat
34 Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee Completed NCT00443092 Phase 4
35 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
36 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
37 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4 colchicine
38 Anti-platelet Effects of Colchicine in Healthy Volunteers Completed NCT02140372 Phase 4 Colchicine
39 Colchicine in Coronary Artery Bypass Graft (CABG) Completed NCT02122484 Phase 4 Colchicine
40 Drug Interaction Study of Colchicine and Theophylline Completed NCT01601132 Phase 4 theophylline;colchicine
41 Cochicine Treatment for Post- Operative Pericardial Effusion Completed NCT01266694 Phase 4 Colchicines;Placebo
42 A Pilot Study for PK/PD Parameter of Colchicine in Chronic Kidney Disease Patient. Completed NCT01173107 Phase 4 colchicine
43 Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) Completed NCT01084278 Phase 4 Colchicine
44 Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain Completed NCT00917436 Phase 4 Thiocolchicoside
45 EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes Completed NCT00272532 Phase 4 Thiocolchicoside
46 Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment. Completed NCT00235079 Phase 4 Colchicine;Placebo
47 Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion Completed NCT02752633 Phase 4 Allopurinol;Febuxostat
48 Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? Completed NCT02237339 Phase 4 Allopurinol;Placebo
49 Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3 Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
50 Ranibizumab Plus Indomethacin Completed NCT03261635 Phase 4 Ranibizumab Injection;Indomethacin

Search NIH Clinical Center for Gout

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: gout

Genetic Tests for Gout

Anatomical Context for Gout

The Foundational Model of Anatomy Ontology organs/tissues related to Gout:

18
Joint

MalaCards organs/tissues related to Gout:

38
Kidney, Heart, Endothelial, Testes, Liver, Skin, Brain

Publications for Gout

Articles related to Gout:

(show top 50) (show all 1041)
# Title Authors Year
1
The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring. ( 29449500 )
2018
2
Managing Gout in the Patient with Renal Impairment. ( 29435850 )
2018
3
Improved Gout Outcomes in Primary Care Using a Novel Disease Management Program: A Pilot Study. ( 29438607 )
2018
4
Hypouricaemic effects of yogurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout: a randomized, double-blind, placebo-controlled study. ( 29446654 )
2018
5
Paraparesis revealing tophaceous gout. ( 29409109 )
2018
6
Gout as a risk factor for osteoporosis: epidemiologic evidence from a population-based longitudinal study involving 108,060 individuals. ( 29383389 )
2018
7
Correction to: Retinal complications of gout: a case report and review of the literature. ( 29402259 )
2018
8
Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. ( 29447370 )
2018
9
Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein. ( 29450849 )
2018
10
Health-related quality of life in gout in primary care: Baseline findings from a cohort study. ( 29398125 )
2018
11
Gout: A Disease of Kings. ( 29393108 )
2018
12
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia. ( 29318274 )
2018
13
Burden of gout in the Nordic region, 1990-2015: findings from the Global Burden of Disease Study 2015. ( 29376465 )
2018
14
Gout drugs use and risk of cancer: A case-control study. ( 29427783 )
2018
15
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. ( 29363262 )
2018
16
Gout (1st Edition). ( 28042131 )
2017
17
Rigid bronchoscopic stenting in a patient of tracheobronchial gout - perioperative anesthetic concerns. ( 29416261 )
2017
18
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin; Methodologic Issues. ( 28927545 )
2017
19
Patient education is vital in gout management. ( 28857011 )
2017
20
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment. ( 28074640 )
2017
21
Gout in immigrant groups: a cohort study in Sweden. ( 28091806 )
2017
22
Impact of non-adherence on the safety and efficacy of uric acid lowering therapies in the treatment of gout. ( 28888218 )
2017
23
Patients with gout have short telomeres compared with healthy participants: association of telomere length with flare frequency and cardiovascular disease in gout. ( 28347991 )
2017
24
Acute Gout: ACP Provides Guideline on Diagnosis. ( 29431400 )
2017
25
Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment. ( 28891365 )
2017
26
Multiple Tophaceous Gout of Hand with Extensor Tendon Rupture. ( 29423326 )
2017
27
GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. ( 27899376 )
2017
28
An Unusual Case of Familial Adenomatous Polyposis Presenting with Gout and Jaundice. ( 28944114 )
2017
29
Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). ( 28794514 )
2017
30
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. ( 28089200 )
2017
31
Spinal Gout Without Spinal Symptom in a Junior School Student: A Case Report. ( 28885290 )
2017
32
Treatment of gout combined with KienbAPck's disease: A case report. ( 29067099 )
2017
33
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin. ( 28065770 )
2017
34
Association of gout and depression: A systematic review and meta-analysis. ( 28921661 )
2017
35
Investigation into the association between P2RX7 gene polymorphisms and susceptibility to primary gout and hyperuricemia in a Chinese Han male population. ( 28243797 )
2017
36
Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand MA8ori and Pacific Men. ( 28371506 )
2017
37
Clinical significance of delta neutrophil index in the differential diagnosis between septic arthritis and acute gout attack within 24 hours after hospitalization. ( 28746185 )
2017
38
Gout: Diagnosis and Management. ( 29431386 )
2017
39
Lytic Bone Lesions: Osteomyelitis or Intraosseous Gout? ( 28864666 )
2017
40
Depression and anxiety correlate with disease-related characteristics and quality of life in Chinese patients with gout: a case-control study. ( 28942667 )
2017
41
An association of smoking with serum urate and gout: A health paradox. ( 29398126 )
2017
42
Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. ( 28866649 )
2017
43
Racial differences in health-related quality of life and functional ability in patients with gout. ( 28028159 )
2017
44
Associations between SLC2A9 polymorphisms and gout susceptibility : AA meta-analysis. ( 27052299 )
2017
45
Assessing Elementary Lesions in Gout by Ultrasound: Results of an OMERACT Patient-based Agreement and Reliability Exercise. ( 28042133 )
2017
46
Intraarticular calcifying aponeurotic fibroma of the wrist: mimicking gout or calcium pyrophosphate dihydrate deposition disease. ( 29243144 )
2017
47
Benefit-risk of corticosteroids in acute gout patients: An updated meta-analysis and economic evaluation. ( 28899726 )
2017
48
Gout Mimicking Soft Tissue Tumor. ( 28863877 )
2017
49
Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study. ( 28877949 )
2017
50
Potential contribution of the neurodegenerative disorders risk loci to cognitive performance in an elderly male gout population. ( 28953682 )
2017

Variations for Gout

Expression for Gout

Search GEO for disease gene expression data for Gout.

Pathways for Gout

Pathways related to Gout according to KEGG:

36
# Name Kegg Source Accession
1 Purine metabolism hsa00230